Evaluation of a PillCam Colon Bowel Preparation Regimen in Crohn's Disease Patients

Crohn's Disease Clinical Trial

— RD-207  

Official title:

Evaluation of a PillCam Colon Bowel Preparation Regimen in Crohn's Disease Patients- Pivotal Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01576120
• Other study ID #: RD-207
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: March 2012
• Est. completion date: July 2014

Study information

• Verified date: October 2014
• Source: Medtronic - MITG
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The proposed study is designed to evaluate Pillcam regimen in Crohn's disease patients, using the PillCam Colon system.

Description:

1. Primary Scientific Objective Evaluate the effectiveness of the PillCam COLON 2 Prep Regimen in CD patients.

Secondary Objective To evaluate safety of the PillCam™ COLON 2 procedure in CD patients

2. Study Hypothesis Crohn's Disease may be pan-enteric in nature and can affect the small bowel, the colon or both. PillCam COLON 2 may be used for visualization of both SB and colon mucosa in Crohn's Disease patients. However, bowel prep is required in order to evacuate all fecal matter prior to the exam and in order to propel the capsule and complete its traverse through the entire GI track within examination time.

3. The study is designed to evaluate the effectiveness of the prep regimen in terms of transit, excretion and cleansing in CD patients

All end points will be evaluated within 4 months from end of enrollment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: July 2014
• Est. primary completion date: July 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Subject is 18 years of age and above

• Subjects who are determined by their physician to have active Crohn's disease based on at least one of the following tests which were performed in the past 3 months :

• Colonoscopy

• Capsule endoscopy of the small bowel or colon

• Other radiology tests

• Clinical symptoms with elevated positive inflammatory markers ;ESR, CRP, thrombocytosis, leukocytosis, fecal lactoferrin, or fecal alpha-1 antitrypsin

• Proven patency by the Agile capsule or another approach deemed clinically acceptable by the investigator, e.g. CT enterography, performed within the 3 months prior to enrollment

• Subject is able and agrees to sign the Informed Consent Form

Exclusion Criteria:

• • Subject has dysphagia

• Subject has congestive heart failure

• Subject has renal insufficiency

• Subject has cirrhosis

• Subject is known or is suspected to suffer from intestinal obstruction

• Subject has known previous stricture/obstruction of the SB or colon

• Chronic use of laxatives

• Subject has a cardiac pacemaker or other implanted electro medical device.

• Women who are either pregnant or nursing at the time of screening, who intend to be during the study period, or are of child-bearing potential and do not practice medically acceptable methods of contraception.

• Subject is expected to undergo MRI examination within 7 days after ingestion of the capsule.

• Subject has had prior abdominal surgery of the gastrointestinal tract other than uncomplicated procedures that would be unlikely to lead to bowel obstruction based on the clinical judgment of the investigator.

• Subject has any condition, which precludes compliance with study and/or device instructions.

• Subject suffers from life threatening conditions

• Subject is currently participating in another clinical study

• Subject has known slow gastric emptying time or GI transit time.

• Subject is allergic or contraindicated to any of the study medications

Related Conditions & MeSH terms

• Crohn Disease
• Crohn's Disease

Intervention

Other:
• bowel prep regimen first boost 6 oz. and second boost 3 oz.
Subjects will be instructed to perform the bowel preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure. In this arm the subjects administered a 6 oz. dose of Suprep as first boost and if needed addtional 3 oz. of Suprep (second boost)
• bowel prep regimen first boost 3 oz. and second boost 6 oz.
Subjects will be instructed to perform the bowel preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure. In this arm the subjects administered a 3 oz. dose of Suprep as first boost and if needed addtional 6 oz. of Suprep (second boost)

Locations

Country	Name	City	State
United States	Atlanta Gastroenterology Associates	Atlanta	Georgia
United States	Dayton Gastroenterology	Beavercreek	Ohio

Sponsors (1)

Lead Sponsor	Collaborator
Medtronic - MITG

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	• Evaluate the Effectiveness of the PillCam COLON 2 Bowel Prep Regimen in Crohn's Disease Patients	effectiveness of the PillCam COLON 2 bowel prep regimen in Crohn's Disease patients will be evaluated by the folloiwng: • Bowel preparation cleansing level assessment; The duration of the procedure in this study is 1 day of colon preparation and; 1 day of Capsule Endoscopy (CE) procedure. 5-9 days after the CE procedure a follow up call to the subjects will be conducted.	The end points and outcomes measures will be evaluated within 4 months from end of enrollment